Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)

Completed

• Conditions: Dyslipidemia; Diabetes

• Registration Number: NCT00526552
• Lead Sponsor: AstraZeneca

Brief Summary

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06
• Primary Completion: 2007-08
• Study First Submitted: 2007-09-05
• Study First Submitted QC: 2007-09-06
• Study First Posted: 2007-09-10
• Study Completion: 2007-12
• Status Verified: 2010-03
• Last Update Submitted: 2010-03-29
• Last Update Posted: 2010-03-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

• Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria

  1. Over 18 years of age
  2. Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician

Read More

Exclusion Criteria

1. Patients already taking other hyperlipidemic agents
2. Patients who do not fulfil the indication criteria for statin therapy
3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Research Site; 🇰🇷 Seoul, Songpa-gu, Korea, Republic of